The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Open accessAbstract
Background and Aims Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. Methods We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. Results At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m 2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m 2 ; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years ( P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years ( P < .001). Conclusions In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
The cited source says what the claim attributes to it.
In the citing paper
“Wound healing in the liver is dynamic and reversible,105 with ample evidence of fibrosis regression after effective treatment of viral hepatitis, and even following bariatric surgery in patients with NASH.106”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [16]
In the citing paper
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“In a long-term follow-up study of patients with MASH who underwent bariatric surgery, the resolution of MASH in liver samples was observed from 84% of patients 5 years later.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“Weight loss either through lifestyle intervention68 or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)69,70 improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.125”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [70]
In the citing paper
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in non-cirrhotic liver, but unlike in HCV and HBV there is no evidence yet that cirrhosis in MASH is reversible (259).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,859
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Cited by
Sorted by citations
Items 301–400 of 620
Poljo, A., Kopf, S., Sulaj, A., Roessler, S., Albrecht, T., Goeppert, B., Bojko, S., Müller-Stich, B., & Billeter, A. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.07.005 · Cited by 9
Rouhi, A. D., Castle, R., Hoeltzel, G. D., Williams, N. N., Dumon, K. R., Baimas‐George, M. R., Wachs, M. E., Nydam, T. L., & Choudhury, R. A. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07102-x · Cited by 8
Alcohol associated liver disease and bariatric surgery: Current perspectives and future directions
Cooper, K. M., Colletta, A., Hebda, N., & Devuni, D. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i3.650 · Cited by 8
“…bariatric surgery can reduce hepatic fibrosis and/or eliminate steatohepatitis in 70%-80% of patients achieving a minimum 5-10-kilogram weight loss[50], it remains unclear if the liver continues to be predisposed to alcohol-associated damage, particularly when exposed to relatively higher…”
Bariatric surgery post-liver transplantation: A Belgian nationwide study
Onghena, L., Geerts, A. M., Berrevoet, F. C., Pirenne, J., Verbeek, J., Bonaccorsi‐Riani, E., Dahlqvist, G., Vonghia, L., Detry, O., Delwaide, J., et al. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000372 · Cited by 8
“[8,9,27,30,40,41] Combined with the safety and feasibility of SG in a post-LT setting, it can be considered an established treatment option in selected patients after LT.”
Wang, Q., Guo, Y., Chen, S., Liu, Z., Wang, X., Huang, H., Shen, Q., Yang, L., Li, M., Li, Y., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01445-w · Cited by 8
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 10
“Bariatric surgery can also resolve MASH and improve hepatic fibrosis [95,96].”
Davis, J. P. E., Reticker, A., Han, H. H., Orandi, B. J., Henry, Z. H., Tsunoda, S. M., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., & the AST LICOP Controversies Conference Working Group (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000645 · Cited by 8
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 11
“Even if initially the fibrosis is advanced, for more than 50% of cases a complete fibrosis resolution may be achieved [201].”
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 9
Self-citationImmunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Osteoarthritis in patients with obesity: The bariatric surgery impacts on its evolution
Eymard, F., & Aron‐Wisnewsky, J. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105639 · Cited by 9
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155721 · Cited by 8
Clinical Perspectives, Eligibility, and Success Criteria for Bariatric/Metabolic Surgery
Perdomo, C. M., Landecho, M. F., Valentí, V., Moncada, R., & Frühbeck, G. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_23 · Cited by 8
Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!
Ziogas, I. A., Zapsalis, K., Giannis, D., & Tsoulfas, G. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i10.709 · Cited by 8
Vily‐Petit, J., Barataud, A., Zitoun, C., Gautier‐Stein, A., Sérino, M., & Mithieux, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-04902-y · Cited by 8
Future of bariatric surgery beyond simple weight loss: Metabolic surgery
Caiazzo, R. J., Marciniak, C., Rémond, A., Baud, G., & Pattou, F. N. (2023) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2023.01.005 · Cited by 11
Self-citationLiver Cancer Reduction After Bariatric Surgery: Time to Expand Its Indication?
Ramai, D., & Facciorusso, A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.053 · Cited by 8
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 7
“…shown consistent results with international findings, with meta-analyses [136, 137] suggesting that resolution of hepatic steatosis, steatohepatitis, and fibrosis was observed in over 75% of patients, with different surgical procedures and a reduction in BMI of 13.4 ± 7.4 kg/m² ( P = .017) [138].”
InfluentialImpact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 11
“Long-term resolution of MASH led to fibrosis regression in 70% of patients and complete resolution of fibrosis in 56% by 5 years [148].”
InfluentialMetALD: Genetic Factors and Clinical Outcomes
Israelsen, M. E., Trépo, E., Krag, A. A., & Stender, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2630-0952 · Cited by 7
“31 During the SLD nomenclature consensus agreement,commongeneticvariants,suchasthosein PNPLA3 , TM6SF2 , and HSD17B13 , were recognized to in fl uence the prevalence and severity of SLD. 7 However, these variants were considered disease modi fi ers for both MASLD and ALD and therefore not included as…”
Anastasiou, I. A., Kounatidis, D. C., Honka, M., Vallianou, N. G., Rebelos, E., Karamanolis, N. N., Dalamaga, Μ., Pantos, C. I., & Mourouzis, I. S. (2025) · Metabolites · doi:10.3390/metabo15070434 · Cited by 7
“These benefits include reduced incidence and mortality related to cardiovascular disease (CVD) [4–10], improvements in metabolic-dysfunction-associated steatotic liver disease (MASLD) [11,12], positive effects on polycystic ovary syndrome (PCOS) [13], and improved renal function [14].”
Bariatric Surgery and Incident Development of Obesity-Related Comorbidities
Bader, A. L., Hsu, J. Y., Altieri, M. S., Vollmer, C. M., Lewis, J. D., Kaplan, D. E., & Mahmud, N. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30787 · Cited by 7
Mendoza, Y. P., Pastó, R., Selicean, S. E., & Gracia‐Sancho, J. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102174 · Cited by 7
Mann, J. P., Lefere, S., Buytaert, M., Alisi, A., Arikan, C., Brecelj, J., Brown, R. M., Degrassi, I., Fiore, G., Fitzpatrick, E., et al. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70490 · Cited by 9
Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 8
“39 Concurrently, reducing alcohol consumption and increasing physical activity improve outcomes and should be actively promoted (preferably moderate physical activity >150 min/week or vigorous physical activity >75 min/week).”
Eisenberg, D., Arnow, K. D., Barreto, N. B., Davis‐Lopez, K. M., LaVela, S. L., Frayne, S. M., Nevedal, A., Wu, J. C., & Harris, A. H. S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.643 · Cited by 6
Bariatric Surgery in Kidney Transplant Candidates and Recipients: Experience at an Asian Center
Tan, S. Y. T., Lee, P. C., Ganguly, S., Kek, P. C., Kee, T., Ho, Q. Y., & Thangaraju, S. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21090 · Cited by 7
Global research trends in non-alcoholic fatty liver disease
Putri, W. A., Setiawan, J., Sofyantoro, F., Priyono, D. S., Septriani, N. I., Mafiroh, W. U., Yano, Y., & Wasityastuti, W. (2023) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2023_092 · Cited by 8
Drai, C., Chierici, A. P., Pavone, G., Benamran, D., Alromayan, M., Alamri, A., Anty, R., Liddo, G., & Iannelli, A. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.10.015 · Cited by 7
Kumar, J., Mohsin, S., Hasan, M., Bilal, A. R., Ali, K. M., Umer, A. M., Hadi, D. Z. M., Nandlal, S., & Kumar, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102261 · Cited by 7
Azulai, S., Grinbaum, R., Beglaibter, N., Eldar, S. M., Rubin, M., Carmi, S., Schyr, R. B., Romano‐Zelekha, O., & Ben‐Zvi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122724 · Cited by 9
HCC in metabolic syndrome: current concepts and future directions
Zampaglione, L., Ferrari, J., Pedica, F., & Goossens, N. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.22 · Cited by 7
Xie, Y., Newberry, E. P., Brunt, E. M., Ballentine, S. J., Soleymanjahi, S., Molitor, E. A., & Davidson, N. O. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100123 · Cited by 7
Cardiorenal outcomes in eligible patients referred for bariatric surgery
Dash, S., Everett, K., Jackson, T. D., Okrainec, A., Urbach, D. R., Sockalingam, S., Shah, B. R., & Farkouh, M. E. (2021) · Obesity · doi:10.1002/oby.23294 · Cited by 7
“In a small but significant proportion of patients, NASH- related hospital admissions increased with bariatric surgery; previous studies have indicated that the majority of patients have improvement in NASH with no fibrosis progression, but some patients do experience progression of fibrosis (28,31).”
Ames, J. B., Djerboua, M. K., Terrault, N. A., Booth, C. M., & Flemming, J. A. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/6175913 · Cited by 7
“/is represents a tremendous opportunity to potentially decrease the burden of cirrhosis and progression to decompensation with early identification, lifestyle interventions, consideration for therapeutics, and bariatric surgery [44] with screening essential at the level of primary care.”
BackgroundMeneses, D., Olveira, A., Corripio, R., Méndez, M., Romero, M., Viñuela, I. C., de Villar, N. G. P., & de-Cos-Blanco, A. I. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06153-2 · Cited by 7
“Seven fibrosis risk scores were calculated using different variables: APRI (aspartate transaminase [AST] to platelet ratio index) [18], FIB-4 (age, AST, platelet, alanine transaminase [ALT]) [19], Forns (platelet, gamma glutamyl transferase [GGT], age, total cholesterol) [20], NAFLD fibrosis score (NFS: age, BMI, diab…”
MethodGonzalez, J., Ouazzani, S., Berdah, S. V., Cauche, N., Delattre, C., Peetermans, J. A., Santoro-Schulte, A., Gjata, O., & Barthet, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-24614-7 · Cited by 7
Liver health and the interplay between obesity, alcohol and bariatric surgery
Geerts, A. M., Onghena, L., & Lefere, S. (2023) · Acta gastro-enterologica belgica · doi:10.51821/86.2.11553 · Cited by 7
Combination Treatment in MASLD: The Next Frontier
Tsochatzis, E. A., & Noureddin, M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.021 · Cited by 7
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
“68,69 For individuals suffering from MASLD with a substantial metabolic component associated with hepatic de novo lipogenesis, particularly in relation to overnutrition and malnutrition, an emphasis on modifying their dietary habits becomes essential.”
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Yodoshi, T., Ollberding, N. J., McNeill, M., Ley, S. L., Kirk, S., Kleiner, D. E., Arce‐Clachar, A. C., Bramlage, K., Inge, T. H., Helmrath, M. A., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70766 · Cited by 7
“%) and fibrosis (improvement in 40%–70%), as shown in large cohort studies [15, 16].”
Loomba, R. S., George, J., Castéra, L., Francque, S., Lawitz, E., Shoeb, A., Clausen, J. O., Andersen, B., Larsen, A. B., & Gluud, L. L. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00123-8 · Cited by 7
Pereira, L. H., de BARROS, F., de Andrade, T. G., Albano, A., Villela‐Nogueira, C. A., & Valezi, A. C. (2024) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720202400028e1821 · Cited by 6
“There is scientific evidence that BMS is the primary and best treatment for MASLD in patients with obesity, showing improvement in steatosis and progressive regression of fibrosis in the long term, likely associated with weight loss 20,33 .”
BackgroundRamesh, P., Krishnan, P., Prabu, S., Srinivasan, V., & Niranjan, V. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100142 · Cited by 5
“Bariatric surgeries for weight loss have also shown promising results with long term resolution and regression of fibrosis in patients with MASLD [74].”
BackgroundWentworth, B. J. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.45 · Cited by 6
Metabolic Surgery: Paradigm Shift in Metabolic Syndrome/Diabetes Therapy
Rühle, A., Billeter, A. T., & Müller-Stich, B. P. (2022) · Visceral Medicine · doi:10.1159/000521707 · Cited by 6
Sasaki, A., Umemura, A., Ishida, K., Takahashi, N., Nikai, H., Nitta, H., Takikawa, Y., Kakisaka, K., Abe, T., Nishiya, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020453 · Cited by 6
“001) at one year after bariatric surgery [28,29].”
BackgroundA Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
Young, E. N., Doğan, M., Watkins, C. E., Bajwa, A., Eason, J. D., Kuscu, C., & Kuscu, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911805 · Cited by 6
“In a recent long term follow-up study, NASH resolution in liver samples was observed in 84% of patients 5 years after bariatric surgery, and the reduction in liver fibrosis was most prominent in the first year with continued progression through 5 years [74].”
BackgroundSchmitz, S. M., Storms, S., Koch, A. H., Stier, C. K., Kroh, A., Rheinwalt, K. P., Schipper, S., Hamesch, K., Ulmer, T. F., Neumann, U. P., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061595 · Cited by 6
Izzy, M. J., Alexopoulos, S. P., & Shingina, A. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100292 · Cited by 6
“2% (1/19 patients) progressed to cirrhosis.(3) Comparable rates of fibrosis regression were noted in other studies in NASH after significant weight loss and in hepatitis C after sustained virological response (SVR).”
BackgroundLi, J., Zhang, D., Liu, P., Fang, R., Li, Y., Zhu, Y., Dong, M., Xie, S., Liu, Y., Wu, J., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120333 · Cited by 5
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
“Both procedures have significant benefits in patients with MASLD, including improved liver histology, resolution of stea-tohepatitis, and reduced fibrosis progression [38].”
Diagnostic et évaluation de l’hépatopathie stéatosique métabolique
Canivet, C. M., & Faure, S. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.10.438 · Cited by 5
Yu, T., Wang, L., Cheng, Y., Zhang, Y., Zhu, J., Zhang, G., & Hu, S. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150264 · Cited by 5
Short-Term Evolution of MASLD Following Roux-en-Y Gastric Bypass: A Focus on Fibrotic MASH
Matavelli, C. B., Echeverria, L. S., Pereira, L. M., Chrispim, I., Mounzer, D. L. S., Chaim, F. D. M., Chaim, É. A., Utrini, M. P., Gestic, M. A., Callejas-Neto, F., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07688-w · Cited by 5
“[10, 14–16] Currently, there is extensive evidence regarding the impact of bariatric surgery on fibrotic MASH; however, there is no study that previously evaluated the use of FNI score to assess this MASLD aspect in individuals undergoing surgery.”
Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment
Канорский, С. Г. (2021) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2021-2-3-18-29 · Cited by 5
Implementation of Cardiometabolic Centers and Training Programs
Taha, M. B., Rao, N., Vaduganathan, M., Cainzos‐Achirica, M., Nasir, K., & Patel, K. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01459-y · Cited by 5
The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease
Berry, P., & Kotha, S. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/21-00217 · Cited by 5
Courtalin, M., Verkindt, H., Daoud, N. O., Ramdane, N., Cortet, B., Pattou, F. N., & Paccou, J. (2023) · Nutrients · doi:10.3390/nu15041007 · Cited by 5
“The OBESE CLASSIQUE cohort is a database compiled from the files of PwO operated on in the Lille University Hospital’s Metabolic Surgery Department [22].”
MethodSelf-citationChiyanika, C., Hui, S. C. N., Sin, D. M. C., Shumbayawonda, E., Wong, S. K. H., Ng, E. K., Yip, T. C., Wong, V. W., & Chu, C. W. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-148 · Cited by 5
Recompensation of cirrhosis in candidates of transplant: Tips and tricks for delisting
Tonon, M., Gagliardi, R., Zeni, N., & Piano, S. S. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000409 · Cited by 5
“Bariatric surgery has excellent results in patients with MASLD, leading to the reduction of fibrosis and steatohepatitis [25] ; however, it is contraindicated in patients with decompensated cirrhosis.”
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Basa, M. L., Cha, D. S., Mitchell, D. P., & Chan, D. L. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.22 · Cited by 5
Duodenal mucosal resurfacing for nonalcoholic fatty liver disease
Shamseddeen, H., Vuppalanchi, R., & Gromski, M. A. (2022) · Clinical Liver Disease · doi:10.1002/cld.1255 · Cited by 4
Aldossari, K. K. (2023) · African Health Sciences · doi:10.4314/ahs.v23i2.59 · Cited by 5
Forlano, R., Stanic, T., Jayawardana, S., Mullish, B. H., Yee, M. S., Mossialos, E. A., Goldin, R. D., Petta, S., Tsochatzis, E. A., Thursz, M. R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2135338/v1 · Cited by 5
Norouzian Ostad, A., Rajabzadeh, F., Jamialahmadi, T., Goshayeshi, L., Ranjbar, G., Rezvani, R., Nematy, M., & Jangjoo, A. (2023) · Updates in Surgery · doi:10.1007/s13304-022-01421-3 · Cited by 4
“Therefore, bariatric surgery is considered the most effective therapy for obesity that had potentially reversed the histology and elastography of NAFLD and spared the liver from progressive damage in cohort studies [30, 32].”
BackgroundCurrently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“Bariatric surgery studies confirmed, however, that weight loss, irrespective of how it is achieved, is associated with improvement in histological features [14] in severely obese individuals [15, 16].”
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 4
PDK2: An Underappreciated Regulator of Liver Metabolism
Woolbright, B. L., & Harris, R. A. (2021) · Livers · doi:10.3390/livers1020008 · Cited by 4
“It should be noted that bariatric surgery is an effective treatment for NASH, and thus it stands to reason that management of metabolism may be an effective treatment for reducing NASH progression and improving outcomes [68].”
BackgroundCan Nonalcoholic Steatohepatitis Be Surgically Cured?
Aminian, A., Wilson, R. L., Al‐Kurd, A., Bena, J., Fayazzadeh, H., Alkhouri, N., Nissen, S. E., & Dasarathy, S. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005914 · Cited by 4
“8 – 10 However, there are no published data comparing the effects of metabolic surgery with nonsurgical care on the histologic progression of NASH.”
BackgroundFrey, S., Ayer, A., Sotin, T., Lorant, V., Louis-Gaubert, C., Arnaud, L., Billon‐Crossouard, S., Croyal, M., Prieur, X., Hadjadj, S., et al. (2023) · Obesity · doi:10.1002/oby.23916 · Cited by 4
“NASH resolved, without worsening fibrosis, in 84% of patients 5 years after bariatric surgery [7].”
BackgroundInfluentialBrol, M. J., Drebber, U., Yu, X., Schierwagen, R., Gu, W., Plamper, A., Klein, S., Odenthal, M., Uschner, F. E., Praktiknjo, M., et al. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.02.006 · Cited by 4
Haddad, G., Gestic, M. A., Utrini, M. P., Chaim, F. D. M., Chaim, É. A., & Cazzo, E. (2024) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612023-050 · Cited by 4
“…time of surgery, it is likely that some NASH features could have been mitigated by the initial weight loss; however, as fibrosis is usually more refractory to weight loss than inflammation, balloo-ning, and steatosis, the rate of fibrosis currently observed is seemingly disproportionate (40-42) .”
No Difference in Liver Damage Induced by Isocaloric Fructose or Glucose in Mice with a High-Fat Diet
Hsu, W., Lee, M.-H., Lii, C., & Peng, C. (2024) · Nutrients · doi:10.3390/nu16203571 · Cited by 4
“Bariatric surgery results in the amelioration of steatosis, MASH, and liver fibrosis [30,31].”
BackgroundOnghena, L., Heldens, A., Paepe, K. D., Antwi, M. B., Vlierberghe, H. V., Raevens, S., Verhelst, X., Hoorens, A., Devisscher, L., Nieuwenhove, Y. V., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002502 · Cited by 4
Behavior of Iron and Ferritin After Bariatric Surgery in Patients With and Without Hepatic Steatosis
Júnior, G. D. C. L., Lacerda, M. D., Alencar, T. A. L. B., Café, M., & Giuffrida, F. M. A. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05629-x · Cited by 4
Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
Schwartz, S. L., Lucas, J., DeLegge, M. H., & IQVIA, R. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.112 · Cited by 4
“In a retrospective analysis of 64 patients with biopsy-confirmed NASH who received bariatric surgery, 84% of patients revealed resolution of steatohepatits and 72% experienced fibrosis regression at follow-up liver biopsy 5 years later.(65) Bariatric surgery has also been shown to reduce overall cardiovascular mortali…”
BackgroundChen, J., Lei, S., Huang, Y., Zha, X., Gu, L., Zhou, D., Li, ., Liu, F., Li, N., Du, L., et al. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01622-0 · Cited by 4
“For both retrospective and prospective cohort studies, NAFLD was improved after bariatric surgery after evaluating serum biomarkers, hepatic steatosis, inflammation, and fibrosis [10, 11].”
BackgroundKasmi, S., Artru, F., Barbosa, J. V., Deibel, A., Favre, L., Peuble, C., Saouli, A.-C., Goossens, N., Müllhaupt, B., Pascual, M. A., et al. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30138 · Cited by 4
Simino, L. A. D. P., Fontana, M. F., de Fante, T., Panzarin, C., Ignácio-Souza, L. M., Milanski, M., Torsoni, M. A., Desai, M., Ross, M. G., & Torsoni, A. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830009 · Cited by 4
“The progression of NAFLD to more severe conditions may require surgical intervention, such as bariatric surgery, liver transplantation, or partial hepatectomy (PHx), the latter involving the removal of the injured tissue to preserve the organ functions (Koppe, 2014; Shingina et al., 2019; Lassailly et al., 2020).”
BackgroundTangible Resources for Multidisciplinary Treatment of Patients With Nonalcoholic Fatty Liver Disease
Abbas, D., Fix, O. K., Evon, D. M., & Barritt, A. S. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001989 · Cited by 4
Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review
Demidova, T. Y., & Омариевна, У. Ф. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202435 · Cited by 4
Yu, T., Ma, X., Yang, C., Wang, Z., Zhang, G., Ding, H., Yin, J., Wang, Y., & Hu, S. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001387 · Cited by 4
“Several studies have demonstrated that after bariatric surgery in patients with NAFLD, liver steatosis is reduced, as evidenced by a signi fi cant decrease in the number of balloon cells and related biochemical indicators in liver tissue sections [6] .”
Treatment and Management of Gastrointestinal Disorders
Montgomery, G., Patel, A., & Pfeil, S. A. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.010 · Cited by 4
How will NAFLD change the liver transplant landscape in the 2020s?
Villeret, F., Dumortier, J., & Erard‐Poinsot, D. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101759 · Cited by 4
Revelo, X. S., Fredrickson, G., Florczak, K. L., Barrow, F., DIETSCHE, K. B., Wang, H., Parthiban, P., Almutlaq, R. N., Adeyi, O. A., Herman, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3446960/v1 · Cited by 4
Angelini, G., Panunzi, S., Pompili, M., Riccardi, L., Garcovich, M., Verrastro, O., Russo, S. L. M. L., Mare, T. A., Luxton, J., le Roux, C. W., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae208 · Cited by 3
Li, M., Wang, X., Zeng, N., Wu, Z., Yu, C., Sun, D., Liu, Y., Cao, D., Zhang, P., Yang, L., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08031-z · Cited by 3
“Previous studies have shown that bariatric surgery provides long-term resolution of NASH and regression of fibrosis, and is associated with lower risks of cardiovascular disease (CVD), cancer, and all-cause mortality [6–8].”
Stupalkowska, W., Henney, A. E., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70173 · Cited by 6
“10 Hagstrom et al. 25 reported on participants from the Swedish Obese Subjects Study, where VBG was the predominant bariatric procedure.”
Longsomboon, R., Kachornvitaya, P., Prasoppokakorn, T., Treeprasertsuk, S., Boonchaya‐anant, P., Klaikaew, N., & Udomsawaengsup, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04482-x · Cited by 3
“Agarwal et al. [14] observed fibrosis regression in 51.7% of patients after 12 months of follow-up, and Las-sailly et al. [9] reported improvement in 74% of Western patients with longer-term follow-up.”
InfluentialCobbold, J. F., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E. D., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 3
The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction
González-Serrano, S., Onoiu, A.-I., Jiménez-Franco, A., Cambra-Cortés, V., Camps, J., & Joven, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797949 · Cited by 3
“Lifestyle modi fi cation remains the fi rst-line approach for weight reduction, while bariatric surgery is considered the most effective intervention for severe obesity (172, 173).”
Gut microbiota turn up the heat after bariatric surgery
Hankir, M. K. (2023) · Cell Stress · doi:10.15698/cst2023.10.290 · Cited by 4
“These surgeries not only cause unparalelled levels of weight loss (up to 25-35%) [5], but also induce a host of other metabolic benefits including remission of the type 2 diabetes [6] and amelioration of the fatty liver disease [7] that usually accompany obesity.”
BackgroundThe Use of Noninvasive Scores in Predicting NAFLD Progression After Bariatric Surgery
Ahmed, L., Gebran, S. G., Persaud, A., Saeed, K., Khan, K., Saeed, S., Alothman, S., Fox, B. P., DePaz, H. A., & Suman, P. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06912-9 · Cited by 3
“Bariatric surgery is the most effective and durable treat-ment for achieving weight loss and is known to impact liver function positively [7–10].”
BackgroundKey genes involved in nonalcoholic steatohepatitis improvement after bariatric surgery
Chen, X., Deng, S., Sun, Y., Bai, Y., Wang, Y., & Yang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338889 · Cited by 4
Kitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Metadata
- Authors
- Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pattou, François
- Mathurin, Philippe
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 159
- Issue
- 4
- Pages
- 1290-1301.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3034346518
- Cited by
- 622
- References
- 27
- Citations by year
- 2026: 93 · 2025: 105 · 2024: 109 · 2023: 106 · 2022: 108 · 2021: 89 · 2020: 11
- FWCI
- 56.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- European Regional Development Fund
- Agence Nationale de la Recherche (ANR-10-LABX-46, ANR-16-RHUS-0006)
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, liver fibrosis regression, obesity, long-term outcomes, weight loss, NASH resolution, liver biopsy histology, bridging fibrosis, metabolic surgery, liver cancer risk, liver transplantation risk
- MeSH terms
- Adult, Biopsy, Female, Follow-Up Studies, France, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Obesity, Morbid, Prospective Studies, Remission Induction, Time Factors, Weight Loss, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
